A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women
NCT ID: NCT04138056
Last Updated: 2024-08-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
509 participants
INTERVENTIONAL
2019-11-05
2021-11-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
NCT04980391
A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
NCT05169905
A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers
NCT04605159
Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety
NCT00263692
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
NCT04424316
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RSV120_dTpa_RSV120(Pooled)
Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and either one dose of 300 μg or 500 μg dTpa (Boostrix) vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
RSVPreF3 formulation 3
One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
Boostrix-ex-US
One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
Boostrix-US
One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.
RSV120_Placebo_RSV120(Pooled)
Subjects received one dose of 120 μg RSVPreF3 formulation 3 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received a second dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
RSVPreF3 formulation 3
One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
Placebo
One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
RSV60_dTpa_RSV120(Pooled)
Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and either one dose of 300 μg or 500 μg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
RSVPreF3 formulation 3
One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
RSVPreF3 formulation 2
One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
Boostrix-ex-US
One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
Boostrix-US
One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.
RSV60_Placebo_RSV120(Pooled)
Subjects received one dose of 60 μg RSVPreF3 formulation 2 vaccine and one dose of Placebo on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
RSVPreF3 formulation 3
One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
RSVPreF3 formulation 2
One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
Placebo
One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
dTpa_Placebo_RSV120(Pooled)
Subjects received one dose of Placebo and either one dose of 300 μg or 500 μg dTpa vaccine on Day 1 of the Primary Study and were followed up until Day 181. The subjects that agreed to participate in the Extension Study received one dose of 120 μg RSVPreF3 formulation 3 vaccine 12 to 18 months post 1st vaccination and were followed up until the study end.
RSVPreF3 formulation 3
One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
Boostrix-ex-US
One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
Boostrix-US
One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.
Placebo
One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RSVPreF3 formulation 3
One dose of RSVPreF3 formulation 3 vaccine administered intramuscularly in the left or in the non-dominant arm.
RSVPreF3 formulation 2
One dose of RSVPreF3 formulation 2 vaccine administered intramuscularly in the left arm.
Boostrix-ex-US
One dose of the dTpa (Ex-US formulation) vaccine administered intramuscularly in the right arm.
Boostrix-US
One dose of the dTpa vaccine (US formulation) administered intramuscularly in the right arm.
Placebo
One dose of placebo (NaCl solution) administered intramuscularly in either the left or the right arm.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Written or witnessed/thumb printed informed consent obtained from the subject prior to performance of any study specific procedure.
* Healthy female subjects; as established by medical history and clinical examination, aged 18 to 45 years at the time of the 1st vaccination;
* Female subjects of childbearing potential may be enrolled in the study, if the subject:
* has practiced adequate contraception for 30 days prior to primary vaccination, and
* has a negative pregnancy test on the day of primary vaccination, and
* has agreed to continue adequate contraception for 90 days after completion of the vaccination.
* No local condition precluding injection in both left and right deltoid muscles.
Extension study
* Completed primary study and received 1st dose of a study vaccine.
* Written or witnessed/thumb printed informed consent obtained from the subject prior to performance of any study specific procedure to the study extension.
All subjects must satisfy ALL the following criteria:
* Subjects who can and will comply with the requirements of the protocol.
* Female subjects remain healthy; as established by medical history and clinical examination, aged 18 to 45 years at the time of the 1st vaccination;
* Female subjects of childbearing potential are eligible for the extension, if the subject:
* has practiced adequate contraception for 30 days prior to 2nd vaccination
* has a negative pregnancy test with results available on the day of 2nd vaccination
* has agreed to continue adequate contraception for 90 days after completion of the 2nd vaccination.
Exclusion Criteria
Medical conditions
* History of any reaction/hypersensitivity likely to be exacerbated by any vaccines' component;
* Any confirmed/suspected immunosuppressive/immunodeficient condition, based on medical history and physical examination;
* Hypersensitivity to latex;
* Major congenital defects;
* Acute/chronic clinically significant pulmonary, cardiovascular, hepatic/renal functional abnormality;
* Significant/uncontrolled psychiatric illness;
* Recurrent history/uncontrolled neurological disorders/seizures;
* Documented HIV-positive subject;
* History of/current autoimmune disease;
* Body mass index (BMI)\>40 kg/m\^2;
* Any clinically significant hematological parameter and/or biochemical laboratory abnormality.
* Any other clinical condition that might pose additional risk to the subject due to participation in the study.
Prior/Concomitant therapy
* Use of any investigational/non-registered product other than the study vaccines during the period starting 30 days before 1st vaccination, or planned use during the study;
* Administration of long-acting immune-modifying drugs at any time during the study;
* Administration of immunoglobulins and/or any blood products/plasma derivatives during the period starting 3 months before the 1st vaccination or planned administration during the study;
* Chronic administration of immunosuppressants/other immune-modifying drugs during the period starting 3 months prior to 1st vaccine dose(s). For corticosteroids, this will mean prednisone ≥5 mg/day, or equivalent. Inhaled and topical steroids are allowed;
* Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after study 1st vaccination, with the exception of any licensed influenza vaccine which may be administered ≥ 15 days before/after study vaccination;
* Administration of a vaccine containing diphtheria, tetanus/pertussis antigens/diphtheria and tetanus toxoids within the previous 5 years;
* Previous experimental vaccination against RSV;
Prior/Concurrent clinical study experience • Concurrently participating in another clinical study, at any time during the study, in which the subject has been/will be exposed to an investigational/a non-investigational vaccine/product;
Other exclusions
* Pregnant/lactating female;
* Female planning to become pregnant/planning to discontinue contraceptive precautions;
* History of alcoholism, drug abuse and/or use disorder within the past 2 years;
* Any study personnel/their immediate dependents, family/household members.
Extension study
Medical conditions
* History of any reaction/hypersensitivity likely to be exacerbated by any component of the vaccines;
* Any confirmed/suspected immunosuppressive/immunodeficient condition, based on medical history and physical examination;
* Hypersensitivity to latex;
* Acute/chronic clinically significant pulmonary, cardiovascular, hepatic/renal functional abnormality;
* Significant/uncontrolled psychiatric illness;
* Recurrent history/uncontrolled neurological disorders/seizures;
* Documented HIV-positive subject;
* History of/current autoimmune disease;
* BMI\>40 kg/m\^2;
* Participants who experienced any SAE judged to be possibly or probably related to 1st dose of RSVPreF3, including hypersensitivity reactions.
* Any other clinical condition that might pose additional risk to the subject due to participation in the study.
Prior/Concomitant therapy
* Use of any investigational/non-registered product other than the study vaccines during the period starting 30 days before the 2nd vaccination, or planned use during the 6-month study extension;
* Administration of long-acting immune-modifying drugs at any time during the study;
* Administration of immunoglobulins and/or any blood products/plasma derivatives during the period starting 3 months before the 1st dose of study vaccines/planned administration during the study;
* Chronic administration of immunosuppressants or other immune-modifying drugs during the starting 3 months prior to the 1st vaccine dose(s). For corticosteroids, this will mean prednisone ≥5 mg/day, or equivalent. Inhaled and topical steroids are allowed;
* Planned administration/administration of a vaccine not foreseen by the study protocol within the period starting 30 days before and ending 30 days after study 2nd vaccination, with the exception of any licensed influenza vaccine which may be administered ≥ 15 days before/after study vaccination.
Prior/Concurrent clinical study experience
• Concurrently participating in another clinical study, at any time during the study, in which the subject has been/will be exposed to an investigational/a non-investigational vaccine/product;
Other exclusions
* Pregnant/lactating female at the time of Visit 4;
* Female planning to become pregnant/planning to discontinue contraceptive precautions;
* History of alcoholism, drug abuse and/or use disorder within the past 2 years;
* Any study personnel/their immediate dependents, family/household members.
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Lenexa, Kansas, United States
GSK Investigational Site
Rochester, New York, United States
GSK Investigational Site
Seattle, Washington, United States
GSK Investigational Site
Ghent, , Belgium
GSK Investigational Site
Leuven, , Belgium
GSK Investigational Site
Truro, Nova Scotia, Canada
GSK Investigational Site
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hermida N, Ferguson M, Leroux-Roels I, Pagnussat S, Yaplee D, Hua N, van den Steen P, Anspach B, Dieussaert I, Kim JH. Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study. J Infect Dis. 2024 Aug 16;230(2):e353-e362. doi: 10.1093/infdis/jiad560.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-002258-22
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
209141
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.